Neuromuscular Disorders Affecting the Action of Rocuronium

Abstract

 Changes in functions of neuromuscular junctions induced by neuromuscular or muscular disorder influence actions of rocuronium and other non-depolarizing neuromuscular blockers. In myasthenia gravis and Lambert-Eaton syndrome, the action of rocuronium is reinforced due to dysfunction of neuromuscular transmission. Action of rocuronium is often enhanced in Duchenne-type muscular dystrophy and myotonic dystrophy, myopathies that impair not only the function of muscle fibers but also the function of neuromuscular junctions. Sepsis often attenuates the action of rocuronium by modulating the function of neuromuscular junctions.